AbbVie Inc

ABBV · Health Technology · Biotechnology · US

57,000 employees · abbvie.com

About

Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines.

Annual results

Reported figures, USD · revenue up 8.6% in 2025

YearRevenueNet incomeNet marginFree cash flow
202561.2B4.2B6.9%—
202456.3B4.3B7.6%17.8B
202354.3B4.9B9.0%22.1B
202258.1B11.8B20.4%24.2B
202156.2B11.5B20.5%22.0B

Dividends per share

2026 6.92 USD2025 6.56 USD2024 6.20 USD2023 5.92 USD2022 5.64 USD

Recent SEC filings

ABBV in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for AbbVie Inc are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Filings from SEC EDGAR. Reported figures, not investment advice.

AbbVie Inc (ABBV) — company profile and financials · MarketPulse